Skip to content

Targovax Receives 2017 Nordic Stars Award

Oslo, Norway, 14 September 2017: Targovax ASA (“Targovax” or “the Company”; OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, today announces that they are one of three companies to have been selected for this year’s Nordic Stars Awards, presented by SwedenBIO.

 This award is given to recognize life science companies in the Nordic region which demonstrate exemplary innovation and entrepreneurial prowess. The prize was awarded at the closing address of the Nordic Life Science Days event on Thursday 14 September 2017.

Øystein Soug, CEO of Targovax, said: “We are delighted to receive this award, which is a testament to the fantastic work the team has done this year. To be recognized amongst many great Nordic companies in the life-science field, is a great honour”.

Nordic Life Science Days
Nordic Life Science Days is the largest Nordic partnering conference for the life science industry. Beginning in 2013, the event continues to attract an international community of leading decision makers from the biotechnology, pharmaceutical and medtech segments, as well as financial, research, policy and regulatory authorities. This year the event attracted over 1070 registered delegates, more than 680 companies & organizations and held 2200+ scheduled meetings.


For further information, please contact:

Renate Birkeli, Investor Relations
Phone: +47 922 61 624

Media and IR enquires:

Jan Petter Stiff – Crux Advisers (Norway)
Phone: +47 995 13 891

Julia Phillips/Simon Conway – FTI Consulting (International)
Phone: +44 20 3727 1000


About Targovax

 Arming the patient’s immune system to fight cancer

 Targovax is a clinical stage company focused on developing and commercializing novel immuno-oncology therapies to target, primarily, treatment-resistant solid tumors. Immuno-oncology is currently one of the fastest growing therapeutic fields in medicine.

 The Company’s development pipeline is based on two novel proprietary platforms:

 The first platform, ONCOS, uses oncolytic viruses as potential multi-target, neo-antigen therapeutic cancer vaccines. ONCOS exclusively uses an adenovirus that has been engineered to be an immune activator that selectively targets cancer cells. In phase I studies it has demonstrated immune activation at lesional level which was associated with clinical benefit. In an ongoing phase I trial in advanced melanoma we expect important proof of concept data for checkpoint inhibitor refractory patients.

 The second, TG, is a target specific, neo-antigen therapeutic cancer vaccine platform that solely targets tumors that express mutated forms of the RAS protein. Mutations to this protein are common in many cancers and are known to drive aggressive disease progression and treatment resistance. There is a high unmet medical need for therapies that are effective against tumors that express these mutations. The TG platform’s therapeutic potential stems from its ability to enable a patient’s immune system to identify and then destroy tumors bearing any RAS mutations. In early 2017, key proof of concept data for the TG platform from a clinical trial of TG01 in resected pancreatic cancer patients showed encouraging overall survival and will give guidance for the future clinical development of this platform.

 Targovax’s development pipeline has three novel therapeutic candidates in clinical development covering six indications.

 Both platforms are protected by an extensive portfolio of IP and know-how and have the potential to yield multiple product candidates in a cost-effective manner. Additionally, Targovax has other products in early stages of development.

 In July 2016, the Company listed its shares on Oslo Axess. In March 2017, the shares moved to Oslo Børs, the main Oslo Stock Exchange.

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

Source: Targovax